Consortium of Eosinophilic Gastrointestinal Disease Researchers

描述（由申请人提供）：本申请旨在通过建立嗜酸性粒细胞性胃肠疾病研究者联盟（CEGIR）促进嗜酸性粒细胞性食管炎（EoE）、嗜酸性粒细胞性胃炎（EG）和嗜酸性粒细胞性结肠炎（EC）的研究。CEGIR包括位于俄亥俄州（协调中心）、科罗拉多、加州、印第安纳州、宾夕法尼亚州、伊利诺伊州、北卡罗来纳州、马萨诸塞州、瑞士和马里兰州的临床中心。所有参与的国内非国立卫生研究院（NIH）临床中心都与临床转化科学奖（CTSA）相关。CEGIR网站是根据其先前存在的相互合作记录精心选择的; 相关临床专业的专业知识，包括胃肠病学，过敏，免疫学和病理学;将儿科和成人患者整合到一个共同的财团的能力;以及在涉及该患者人群的临床研究中建立良好的卓越记录。重要的是，CEGIR研究中心已经证明可以接触到足够数量的罕见疾病患者，最近完成的第一组涉及该患者人群的对照临床试验证明了这一点。强大的患者倡导团体（PAG），包括 美国嗜酸性粒细胞疾病伙伴关系（APFED）和嗜酸性粒细胞疾病研究运动（CURED）已经与CEGIR研究人员合作，并将继续在CEGIR的背景下协同工作。尽管CEGIR研究人员最近取得了进展，他们的合作互动取得了早期成功，积极的PAG以及新型抗嗜酸性粒细胞治疗剂的开发，但目前还没有针对这三种罕见的独特疾病的临床网络的现有资金，突出了该应用的及时性和重要性。

DESCRIPTION (provided by applicant): This application aims to facilitate research on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) through the development of a Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR comprises clinical centers in Ohio (the coordinating center), Colorado, California, Indiana, Pennsylvania, Illinois, North Carolina, Massachusetts, Switzerland, and Maryland. All participating domestic, non-National Institutes of Health (NIH) clinical centers are associated with a Clinical Translational Science Award (CTSA). The CEGIR sites have been carefully chosen on the basis of their preexisting record of collaboration with each other; diverse expertise in relevant clinical specialties including Gastroenterology, Allergy, Immunology, and Pathology; the ability to integrate pediatric and adult patients into a common consortium; and well-established record of excellence in clinical research involving this patient population. Importantly, the CEGIR sites have proven access to an adequate number of patients with the rare diseases studied, as evidenced from the recent completion of the first set of controlled clinical trials involving this patient population. Strong patient advocacy groups (PAGs), including the American Partnership for Eosinophilic Disorders (APFED) and the Campaign Urging Research for Eosinophilic Disease (CURED), already partner with the CEGIR Investigators and will continue to work synergistically in the context of CEGIR. Despite the recent record of advances by CEGIR Investigators, the early success of their collaborative interactions, the proactive PAGs, and the development of novel anti-eosinophil therapeutics, there is no currently existing funding for a clinical network focusing on these three rare, distinct diseases, highlightig the timeliness and importance of this application.